Background: Colorectal cancer is one of the most common cancers worldwide and has a
high mortality rate following disease recurrence. Treatment efficacy is maximized by …

Regorafenib is an oral tyrosine kinase inhibitor (TKI) approved for the treatment of refractory
metastatic colorectal cancer (mCRC), advanced gastrointestinal stromal tumors (GIST) …

Abstract Background OncoBEAMTM RAS CRC kit using BEAMing technology is a circulating
tumour DNA (ctDNA) test for detecting plasma RAS mutational status in metastatic colorectal …

Importance Although quality of life (QOL) is an important clinical end point, cancer drugs are
often approved based on overall survival (OS) or putative surrogate end points such as …

Abstract Treatment with pharmacological drugs for colorectal cancer (CRC) remains
unsatisfactory. A major cause of failure in pharmacotherapy is the resistance of colon cancer …

Objective The efficacy and safety of regorafenib and fruquintinib are studied extensively in
different populations and trials across the world to determine their potential benefits. Here …

Background In the BEACON CRC study (NCT02928224), encorafenib plus cetuximab with
binimetinib {9.3 versus 5.9 months; hazard ratio (HR)[95% confidence interval (CI)]: 0.60 …

Minimal Residual Disease (MRD) detection has emerged as an independent factor in
clinical and pathological cancer assessment offering a highly effective method for predicting …

Over the past 20 years, management of patients with metastatic colorectal cancer (mCRC)
has improved considerably, leading to increased overall survival and more patients eligible …

The progress of metastatic colorectal cancer (mCRC) depends essentially on two signaling
pathways: the first mediated by vascular endothelial growth factor (VEGF) and the second by …